Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMPIONS10: Long-term Avonex in Early MS
NCT00179478Phase 4Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Feb 2001
- Primary completion
- Mar 2009
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 4, open-label trial of interferon beta-1a in multiple sclerosis (MS) (2 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Rate of Development of Clinical Definite Multiple Sclerosis at 10 years. Started Feb 2001; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00179478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179478.